tag:blogger.com,1999:blog-36768584.post5956127919152367978..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: SeqLL: Helicos van WinkleKeith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-36768584.post-73674424132594474032018-02-24T10:41:28.118-05:002018-02-24T10:41:28.118-05:00Hi Keith, just re-reading your post and went to lo...Hi Keith, just re-reading your post and went to look at http://seqll.com/services to see what's changed. The website is offering RNA-Seq but after cDNA conversion, although they do mention the DRS service. There's not a huge amount of information on the site that helps me understand if Helicos can be revived and be commercially successful.<br /><br />I agree with Shawn that if they can get a DRS counting app out that we can use they may be able to carve a niche. But they'd better be quick given the developments of ONTJames@cancerhttps://www.blogger.com/profile/02825715598810395734noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-39752944059038368772016-10-24T23:18:34.088-04:002016-10-24T23:18:34.088-04:00This:
https://www.ncbi.nlm.nih.gov/pubmed/2715186...This:<br /><br />https://www.ncbi.nlm.nih.gov/pubmed/27151869<br /><br />Was truly awesome and only possible with their machine.<br /><br />Also, chromatin assays in organisms with very high-AT genomes would be a great fit for the technology. <br /><br />But those are niche markets indeed. <br /><br />The direct RNA-seq stuff is also great in principle, but it is best suited to 3' end profiling. Which is also a niche market. <br /><br />It doesn't give you full-length RNAs the way the nanopores are promising to. Georgi Marinovhttps://www.blogger.com/profile/12226357993389417752noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-64890081981320443482016-10-24T20:24:51.926-04:002016-10-24T20:24:51.926-04:00Unless they've reduced the price, PacBio's...Unless they've reduced the price, PacBio's Sequel (I wonder how much that name annoys SeqLL) lists for $350k. As for SeqLL, they should focus on what Helicos should have focused on all those years ago - building a short read counting machine for RNA-Seq and ChIP-Seq. I think they're going to struggle with anything else.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-86606176792237022692016-10-24T18:53:39.380-04:002016-10-24T18:53:39.380-04:00Very much agree with advice to target that specifi...Very much agree with advice to target that specific application that SeqLL might be best suited for and that is not currently dominated by other technologies or library prep methods. That's hard to do (nothing pops into my head at the moment), but to get the users jazzed up--who you really need in a case like this--there's gotta be a hook. PacBio is long, long single molecule reads, so phasing and translocations. Oxford is portability, $, and fast pathogen ID. Seems like they may have launched prematurely.<br /><br />I'm all for the concept of letting the users define and develop the use cases and techniques; to me that was Illumina's genius, and something Oxford is doing well too. But there has to be some reason to even get the user to try.Kyle Serikawanoreply@blogger.com